Завершено
Фаза II–III
Россия
ABR-217620/naptumomab estafenatox; IFN-alpha · Active Biotech AB
A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.